Understanding the long-term effects of COVID-19 infection
Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study
This study looks at people who have recovered from COVID-19 to see how the infection affects their health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT04362150 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on individuals who have recovered from COVID-19 to investigate the long-term clinical consequences of SARS-CoV-2 infection. Participants will undergo a series of visits at San Francisco General Hospital, where they will provide saliva and blood samples, as well as detailed clinical data. The study aims to explore immune responses, inflammation, and the development of medical conditions over time, with attention to demographic differences. The collected specimens will contribute to a specimen bank for further research on COVID-19.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have a documented history of SARS-CoV-2 infection and have recovered from acute illness.
Not a fit: Patients with chronic anemia or serious medical or psychiatric illnesses that could interfere with study participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of long COVID and inform better management strategies for patients recovering from COVID-19.
How similar studies have performed: Other studies have shown success in understanding long COVID, making this approach relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to provide written informed consent, and 2. Age \>/= 18 years, and 3. A history of SARS-CoV-2 infection, as evidenced by: 1. Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or 2. Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection, 4. And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier. Exclusion Criteria: 1. Self-reported or documented chronic anemia with hemoglobin \< 9 g/dL. Anemia during a preceding acute illness will not be exclusionary. 2. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent. 3. Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.
Where this trial is running
San Francisco, California
- Zuckerberg San Francisco General Hospital (ZSFG) — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Steven Deeks, MD — University of California, San Francisco
- Study coordinator: Rebecca Hoh
- Email: rebecca.hoh@ucsf.edu
- Phone: 415-476-4082 Ext. 139
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.